Abstract
Adenocarcinoma is now the dominant histological subtype of oesophageal cancer in high-income countries in Europe and North America. Patient outcomes have improved during the past few decades due to centralisation of surgery and implementation of multimodality therapy. However, most patients relapse following curative-intent surgery. Therefore, more effective perioperative treatment options are needed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
